EU-OPENSCREEN has evolved from a visionary blueprint into a fully operational platform since its launch in 2018. The article showcases our key achievements over the past six years and outlines upcoming developments as we continue to expand our technology portfolio in response to emerging trends in drug discovery.

By providing open access to high-throughput screening, chemoproteomics, spatial MS-based omics platforms, and medicinal chemistry expertise, EU-OPENSCREEN supports researchers in discovering biologically active small molecules – the seeds for tomorrow’s chemical tools and therapeutics.

This publication highlights how scientists across Europe can leverage our infrastructure to translate groundbreaking ideas into innovative, real-world applications.

Read the full article here: https://www.slas-discovery.org/article/S2472-5552(25)00021-8/fulltext